EAM
HBIO icon

Eagle Asset Management’s Harvard Bioscience HBIO Stock Holding History

Eagle Asset Management’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,384
Closed -$74K – 586
2023
Q4 		$74K Hold
1,384
– – ﹤0.01% 554
2023
Q3 		$59.5K Hold
1,384
– – ﹤0.01% 533
2023
Q2 		$76K Hold
1,384
– – ﹤0.01% 527
2023
Q1 		$58K Buy
+1,384
New +$41.1K ﹤0.01% 538

Other funds holding HBIO

2C
272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return
AE
AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Eagle Asset Management's HBIO Position: Q1 2024 in Review

Eagle Asset Management sold out of Harvard Bioscience (HBIO) in Q1 2024, closing a stake of 1,384 shares — an estimated $74K sold.

Eagle Asset Management first reported a position in HBIO in Q1 2023 and held it in 4 quarters. The position peaked at $76K in Q2 2023. 89 funds tracked by Wall St. Rank hold HBIO as of Q1 2024.

  • Eagle Asset Management reported no remaining Harvard Bioscience position as of Q1 2024 after selling out during the quarter.
  • Eagle Asset Management sold 1,384 Harvard Bioscience shares in Q1 2024, an estimated $74K.
  • Eagle Asset Management first reported a position in Harvard Bioscience in Q1 2023 and held it in 4 quarters.
  • Eagle Asset Management's Harvard Bioscience position peaked at $76K in Q2 2023.
  • 89 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2024.

Based on Eagle Asset Management's 13F filing for Q1 2024, filed 9 May 2024.